

# Cefiderocol Sulfate Tosylate

AHFS 8:12.06.28

## Products

Cefiderocol sulfate tosylate is available as a lyophilized powder in single-dose vials containing the equivalent of 1 g of cefiderocol.<sup>3531</sup> Each vial also contains sucrose 900 mg, sodium chloride 216 mg, and sodium hydroxide to adjust the pH.<sup>3531</sup>

The contents of each 1-g vial of cefiderocol should be reconstituted with 10 mL of sodium chloride 0.9% or dextrose 5% and the vial should be shaken gently to dissolve the powder.<sup>3531</sup> Vials should be allowed to stand until any foam that has been generated on the surface has disappeared (usually about 2 minutes).<sup>3531</sup> The reconstituted solution must be diluted prior to infusion.<sup>3531</sup>

The manufacturer's instructions for preparing various doses of cefiderocol from the reconstituted solution are as follows.<sup>3531</sup>

For a 2-g dose, withdraw the entire contents of 2 vials (i.e., approximately 11.2 mL per vial).

For a 1.5-g dose, withdraw the entire contents of 1 vial (i.e., approximately 11.2 mL) and 5.6 mL from a second vial.

For a 1-g dose, withdraw the entire contents of 1 vial (i.e., approximately 11.2 mL).

For a 0.75-g dose, withdraw 8.4 mL from 1 vial.

All doses should then be added to a 100-mL infusion bag containing sodium chloride 0.9% or dextrose 5%.<sup>3531 3544</sup>

## pH

The pH of the resulting solution that forms when 1 g of cefiderocol is dissolved in 10 mL of water is within the range of 5.2 to 5.8.<sup>3531</sup>

## Equivalency

Cefiderocol sulfate tosylate 1.6 g is equivalent to 1 g of cefiderocol.<sup>3531</sup>

## Sodium Content

Each 1-g vial of cefiderocol contains approximately 176 mg of sodium.<sup>3531</sup>

## Trade Name(s)

Fetroja

## Administration

Cefiderocol sulfate tosylate is administered by intravenous infusion over 3 hours following reconstitution and further dilution.<sup>3531</sup>

## Stability

Cefiderocol sulfate tosylate is a white to off-white powder that forms a clear, colorless solution upon reconstitution and dilution.<sup>3531</sup> Intact vials of cefiderocol sulfate tosylate should be stored at 2 to 8°C in the original carton until time of use to protect from light.<sup>3531</sup>

After reconstitution with an appropriate diluent as instructed, the drug may be stored for up to 1 hour at room temperature.<sup>3531</sup> Following dilution, the drug is stable for 6 hours at room temperature.<sup>3531</sup> The diluted solution for infusion also may be refrigerated at 2 to 8°C for up to 24 hours when protected from light; administration should be completed within 6 hours at room temperature following refrigerated storage.<sup>3531</sup>

## Compatibility Information

### Solution Compatibility

#### Cefiderocol sulfate tosylate

| Test Soln Name       | Mfr | Mfr | Conc/L or % | Remarks  | Refs | C/I |
|----------------------|-----|-----|-------------|--|------|-----|
| Dextrose 5%          |     | SHI |             | Stable for up to 6 hr at room temperature or up to 24 hr at 2 to 8°C protected from light; following refrigerated storage, complete administration within 6 hr at room temperature | 3531 | C   |
| Sodium chloride 0.9% |     | SHI |             | Stable for up to 6 hr at room temperature or up to 24 hr at 2 to 8°C protected from light; following refrigerated storage, complete administration within 6 hr at room temperature | 3531 | C   |

**Y-Site Injection Compatibility (1:1 Mixture)****Cefiderocol sulfate tosylate**

| Test Drug                             | Mfr | Conc                    | Mfr | Conc                  | Remarks   | Refs       | C/I |
|---------------------------------------|-----|-------------------------|-----|-----------------------|---|------------|-----|
| Acyclovir sodium                      | AUB | 7 mg/mL <sup>c</sup>    | SHI | 20 mg/mL <sup>c</sup> | Visually incompatible upon mixing   | 3662       | I   |
| Albumin human                         | OCT | 250 mg/mL               | SHI | 20 mg/mL <sup>c</sup> | Results of subvisual tests indicate high turbidity with or without particulate matter   | 3662, 3670 | I   |
| Amikacin sulfate                      | SGT | 5 mg/mL <sup>a</sup>    | SHI | 20 mg/mL <sup>a</sup> | Physically compatible for up to 4 hr at 21 to 25°C  | 3662       | C   |
| Amikacin sulfate                      | SGT | 5 mg/mL <sup>b</sup>    | SHI | 20 mg/mL <sup>b</sup> | Results of subvisual tests indicate high counts of particles $\geq 2$ and $\geq 10$ $\mu\text{m}$ when cefiderocol is added to amikacin; not observed when order of mixing was reversed | 3662       | ?   |
| Aminophylline                         | HOS | 1 mg/mL <sup>a</sup>    | SHI | 20 mg/mL <sup>a</sup> | Physically compatible for up to 4 hr at 21 to 25°C  | 3662       | C   |
| Aminophylline                         | HOS | 1 mg/mL <sup>b</sup>    | SHI | 20 mg/mL <sup>b</sup> | Results of subvisual tests indicate high counts of particles $\geq 2$ and $\geq 10$ $\mu\text{m}$   | 3662       | I   |
| Amiodarone HCl                        | WW  | 4 mg/mL <sup>c</sup>    | SHI | 20 mg/mL <sup>c</sup> | Visually incompatible upon mixing   | 3662       | I   |
| Amphotericin B                        | XGN | 1 mg/mL <sup>c</sup>    | SHI | 20 mg/mL <sup>c</sup> | Visually incompatible upon mixing   | 3662       | I   |
| Anidulafungin                         | RR  | 0.77 mg/mL <sup>c</sup> | SHI | 20 mg/mL <sup>c</sup> | Blue haze observed due to Tyndall effects of colloidal-size micelles scattering blue light; turbidity decreased upon mixing   | 3662       | ?   |
| Azithromycin                          | ATX | 2 mg/mL <sup>c</sup>    | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C  | 3662       | C   |
| Aztreonam                             | BMS | 20 mg/mL <sup>c</sup>   | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C  | 3662       | C   |
| Bumetanide                            | WW  | 0.25 mg/mL              | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C  | 3662, 3670 | C   |
| Calcium gluconate                     | FRK | 20 mg/mL <sup>c</sup>   | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C  | 3662       | C   |
| Caspofungin acetate                   | GLA | 0.5 mg/mL <sup>c</sup>  | SHI | 20 mg/mL <sup>c</sup> | Visually incompatible upon mixing   | 3662       | I   |
| Cefazolin sodium                      | HOS | 20 mg/mL <sup>c</sup>   | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C  | 3662       | C   |
| Cefepime HCl                          | QI  | 40 mg/mL <sup>c</sup>   | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C  | 3662       | C   |
| Ceftaroline fosamil                   | FOR | 12 mg/mL <sup>c</sup>   | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C  | 3662       | C   |
| Ceftazidime–avibactam sodium          | GSK | 40 mg/mL <sup>c d</sup> | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C  | 3662, 3670 | C   |
| Ceftolozane sulfate–tazobactam sodium | SPA | 10 mg/mL <sup>c e</sup> | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C  | 3662, 3670 | C   |
| Ciprofloxacin                         | CLA | 2 mg/mL <sup>l</sup>    | SHI | 20 mg/mL <sup>a</sup> | Results of subvisual tests indicate increased turbidity   | 3662, 3670 | I   |
| Ciprofloxacin                         | CLA | 2 mg/mL <sup>l</sup>    | SHI | 20 mg/mL <sup>b</sup> | Physically compatible for up to 4 hr at 21 to 25°C  | 3662, 3670 | C   |
| Cisatracurium besylate                | ABV | 0.4 mg/mL <sup>c</sup>  | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C  | 3662       | C   |
| Clindamycin phosphate                 | SGT | 10 mg/mL <sup>c</sup>   | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C  | 3662       | C   |
| Colistimethate sodium                 | XE  | 4.5 mg/mL <sup>c</sup>  | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C  | 3662       | C   |
| Daptomycin                            | GLA | 20 mg/mL <sup>c</sup>   | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C  | 3662       | C   |
| Dexamethasone sodium phosphate        | FRK | 1 mg/mL <sup>c</sup>    | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C  | 3662       | C   |

*Y-Site Injection Compatibility (1:1 Mixture) (Cont.)*

| Test Drug                       | Mfr | Conc                    | Mfr | Conc                  | Remarks  | Refs       | C/I |
|---------------------------------|-----|-------------------------|-----|-----------------------|--|------------|-----|
| Dexmedetomidine HCl             | AUB | 4 mcg/mL <sup>c</sup>   | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Digoxin                         | SZ  | 250 mcg/mL              | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662, 3670 | C   |
| Diltiazem HCl                   | AKN | 5 mg/mL                 | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662, 3670 | C   |
| Diphenhydramine HCl             | WW  | 50 mg/mL                | SHI | 20 mg/mL <sup>c</sup> | Visually incompatible upon mixing  | 3662, 3670 | I   |
| Dobutamine HCl                  | HOS | 4 mg/mL <sup>c</sup>    | SHI | 20 mg/mL <sup>c</sup> | Visually incompatible upon mixing  | 3662       | I   |
| Doxycycline hyclate             | FRK | 1 mg/mL <sup>c</sup>    | SHI | 20 mg/mL <sup>c</sup> | Visually incompatible upon mixing  | 3662       | I   |
| Epinephrine <sup>k</sup>        | SIN | 16 mcg/mL <sup>c</sup>  | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Ertapenem sodium                | PAR | 20 mg/mL <sup>c</sup>   | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Esomeprazole sodium             | MYL | 0.8 mg/mL <sup>c</sup>  | SHI | 20 mg/mL <sup>c</sup> | Visually incompatible upon mixing  | 3662       | I   |
| Famotidine                      | WW  | 4 mg/mL <sup>c</sup>    | SHI | 20 mg/mL <sup>c</sup> | Visually incompatible upon mixing  | 3662       | I   |
| Fentanyl citrate                | HOS | 50 mcg/mL               | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662, 3670 | C   |
| Fluconazole                     | HOS | 2 mg/mL <sup>l</sup>    | SHI | 20 mg/mL <sup>c</sup> | Results of subvisual tests indicate increased counts of particles <5 µm; counts of particles ≥10 and ≥25 µm within limits. No significant changes in turbidity | 3662       | ?   |
| Furosemide                      | BA  | 3 mg/mL <sup>c</sup>    | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Gentamicin sulfate              | FRK | 5 mg/mL <sup>c</sup>    | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Heparin sodium                  | HOS | 1000 units/mL           | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Hydrocortisone sodium succinate | PF  | 1 mg/mL <sup>c</sup>    | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Hydromorphone HCl               | AKN | 1 mg/mL <sup>c</sup>    | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Imipenem–cilastatin sodium      | FRK | 5 mg/mL <sup>c, f</sup> | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662, 3670 | C   |
| Insulin, regular                | LI  | 1 unit/mL <sup>c</sup>  | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Iron dextran                    | ALL | 25 mg/mL <sup>c</sup>   | SHI | 20 mg/mL <sup>c</sup> | Opaque dark red solution; turbidity decreased upon mixing  | 3662       | ?   |
| Iron sucrose                    | AMR | 20 mg/mL                | SHI | 20 mg/mL <sup>c</sup> | Opaque dark red solution with significant turbidity  | 3662, 3670 | I   |
| Labetalol HCl                   | AVG | 5 mg/mL                 | SHI | 20 mg/mL <sup>c</sup> | Visually incompatible upon mixing  | 3662, 3670 | I   |
| Levofloxacin                    | AUR | 5 mg/mL <sup>c</sup>    | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Lidocaine HCl                   | HIK | 8 mg/mL <sup>c</sup>    | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Linezolid                       | FRK | 2 mg/mL <sup>l</sup>    | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662, 3670 | C   |
| Lorazepam                       | HOS | 1 mg/mL <sup>c</sup>    | SHI | 20 mg/mL <sup>c</sup> | Results of subvisual tests indicate lightly hazy to hazy solutions with or without increased turbidity and a high count of particles ≥2 µm                     | 3662       | I   |
| Magnesium sulfate               | FRK | 100 mg/mL <sup>c</sup>  | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |

*Y-Site Injection Compatibility (1:1 Mixture) (Cont.)*

| Test Drug                  | Mfr              | Conc                              | Mfr | Conc                  | Remarks  | Refs       | C/I |
|----------------------------|------------------|-----------------------------------|-----|-----------------------|--|------------|-----|
| Mannitol                   | HOS              | 20% <sup>c</sup>                  | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Meropenem                  | AMB              | 10 mg/mL <sup>c</sup>             | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Meropenem–vaborbactam      | FAC              | 8 mg/mL <sup>c</sup> <sup>9</sup> | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662, 3670 | C   |
| Methylprednisolone acetate | PF               | 20 mg/mL <sup>c</sup>             | SHI | 20 mg/mL <sup>c</sup> | Visually incompatible upon mixing  | 3662       | I   |
| Metoclopramide HCl         | HOS              | 0.2 mg/mL <sup>c</sup>            | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Metronidazole              | HOS              | 5 mg/mL <sup>l</sup>              | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662, 3670 | C   |
| Micafungin sodium          | ASP              | 4 mg/mL <sup>c</sup>              | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Midazolam HCl              | HOS              | 2 mg/mL <sup>c</sup>              | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Milrinone lactate          | HIK              | 0.2 mg/mL <sup>c</sup>            | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Morphine sulfate           | HOS              | 15 mg/mL <sup>a</sup>             | SHI | 20 mg/mL <sup>a</sup> | Results of subvisual tests indicate high counts of particles $\geq 25$ and $\geq 50$ $\mu\text{m}$ when cefiderocol is added to morphine; not observed when order of mixing was reversed                               | 3662       | ?   |
| Morphine sulfate           | HOS              | 15 mg/mL <sup>b</sup>             | SHI | 20 mg/mL <sup>b</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Multivitamins              | SZ               | 0.02 mL/mL <sup>c</sup>           | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Mycophenolate mofetil HCl  | GEN              | 6 mg/mL <sup>c</sup>              | SHI | 20 mg/mL <sup>c</sup> | Visually incompatible upon mixing  | 3662       | I   |
| Naloxone HCl               | MYL              | 0.04 mg/mL <sup>c</sup>           | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Nicardipine HCl            | HIK              | 0.1 mg/mL <sup>c</sup>            | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Nitroglycerin              | AMR              | 0.4 mg/mL <sup>c</sup>            | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Norepinephrine bitartrate  | TE               | 0.128 mg/mL <sup>c</sup>          | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Octreotide acetate         | TE               | 4 mcg/mL <sup>c</sup>             | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Ondansetron HCl            | HOS              | 0.16 mg/mL <sup>c</sup>           | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Pantoprazole sodium        | AUR <sup>i</sup> | 0.4 mg/mL <sup>c</sup>            | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Phenylephrine HCl          | WW               | 1 mg/mL <sup>a</sup>              | SHI | 20 mg/mL <sup>a</sup> | Results of subvisual tests indicate high counts of particles $\geq 2$ , $\geq 10$ , $\geq 25$ , and $\geq 50$ $\mu\text{m}$ when phenylephrine is added to cefiderocol; not observed when order of mixing was reversed | 3662       | ?   |
| Phenylephrine HCl          | WW               | 1 mg/mL <sup>b</sup>              | SHI | 20 mg/mL <sup>b</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Phenytoin sodium           | WW               | 10 mg/mL <sup>c</sup>             | SHI | 20 mg/mL <sup>c</sup> | Visually incompatible upon mixing  | 3662       | I   |
| Polymyxin B sulfate        | XE               | 1250 units/mL <sup>a</sup>        | SHI | 20 mg/mL <sup>a</sup> | Results of subvisual tests indicate high turbidity   | 3662       | I   |
| Polymyxin B sulfate        | XE               | 1250 units/mL <sup>a</sup>        | SHI | 20 mg/mL <sup>b</sup> | Slight haze forms and gas bubbles evolve   | 3662       | I   |
| Posaconazole               | MSD              | 2 mg/mL <sup>c</sup>              | SHI | 20 mg/mL <sup>c</sup> | Visually incompatible upon mixing  | 3662       | I   |
| Potassium chloride         | HOS              | 0.1 mg/mL <sup>c</sup>            | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Potassium phosphates       | HOS              | 0.3 mmol/mL <sup>c</sup>          | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |

*Y-Site Injection Compatibility (1:1 Mixture) (Cont.)*

| Test Drug                     | Mfr              | Conc                     | Mfr | Conc                  | Remarks  | Refs       | C/I |
|-------------------------------|------------------|--------------------------|-----|-----------------------|--|------------|-----|
| Propofol                      | SGT <sup>†</sup> | 10 mg/mL                 | SHI | 20 mg/mL <sup>c</sup> | Visually incompatible upon mixing  | 3662, 3670 | I   |
| Ranitidine HCl                | CDL              | 2.5 mg/mL <sup>c</sup>   | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Rocuronium bromide            | XGN              | 5 mg/mL <sup>c</sup>     | SHI | 20 mg/mL <sup>c</sup> | Visually incompatible upon mixing  | 3662       | I   |
| Sodium bicarbonate            | HOS              | 1 mEq/mL                 | SHI | 20 mg/mL <sup>a</sup> | Results of subvisual tests indicate a high count of particles ≥25 μm when sodium bicarbonate is added to cefiderocol; not observed when order of mixing was reversed | 3662, 3670 | I   |
| Sodium bicarbonate            | HOS              | 1 mEq/mL                 | SHI | 20 mg/mL <sup>b</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662, 3670 | C   |
| Sodium nitroprusside          | HOS              | 0.4 mg/mL <sup>c</sup>   | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Sodium phosphates             | FRK              | 0.5 mmol/mL <sup>c</sup> | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Succinylcholine chloride      | CDL              | 2 mg/mL <sup>c</sup>     | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Tedizolid phosphate           | PNN              | 0.8 mg/mL <sup>c</sup>   | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Tigecycline                   | LEK              | 1 mg/mL <sup>c</sup>     | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Tobramycin sulfate            | FRK              | 10 mg/mL                 | SHI | 20 mg/mL <sup>c</sup> | Results of subvisual tests indicate the presence of white particles  | 3662, 3670 | I   |
| Trimethoprim–sulfamethoxazole | MYL              | 1 mg/mL <sup>c, h</sup>  | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662, 3670 | C   |
| Vancomycin HCl                | GLA              | 5 mg/mL <sup>a</sup>     | SHI | 20 mg/mL <sup>a</sup> | Visually incompatible upon mixing  | 3662       | I   |
| Vancomycin HCl                | GLA              | 5 mg/mL <sup>b</sup>     | SHI | 20 mg/mL <sup>b</sup> | Results of subvisual tests indicate the presence of cloudiness with white particles  | 3662       | I   |
| Vasopressin                   | PAR              | 1 unit/mL <sup>c</sup>   | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Vecuronium bromide            | TE               | 1 mg/mL <sup>c</sup>     | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |
| Voriconazole                  | PF               | 2 mg/mL <sup>c</sup>     | SHI | 20 mg/mL <sup>c</sup> | Physically compatible for up to 4 hr at 21 to 25°C   | 3662       | C   |

<sup>a</sup> Tested in dextrose 5%.

<sup>b</sup> Tested in sodium chloride 0.9%

<sup>c</sup> Tested in both dextrose 5% and sodium chloride 0.9%.

<sup>d</sup> Ceftazidime component. Ceftazidime in a 4:1 fixed-ratio concentration with avibactam.

<sup>e</sup> Ceftolozane component. Ceftolozane in a 2:1 fixed-ratio concentration with tazobactam.

<sup>f</sup> Imipenem component. Imipenem in a 1:1 fixed-ratio concentration with cilastatin.

<sup>g</sup> Meropenem component. Meropenem in a 1:1 fixed-ratio concentration with vaborbactam.

<sup>h</sup> Trimethoprim component. Trimethoprim in a 1:5 fixed-ratio concentration with sulfamethoxazole.

<sup>i</sup> Test performed using the formulation WITH edetate disodium.

<sup>j</sup> Test performed using the formulation WITHOUT edetate disodium.

<sup>k</sup> Salt not specified.

<sup>†</sup> Tested as the premixed infusion solution.

Selected Revisions July 31, 2021. © Copyright, May 2020.  
American Society of Health-System Pharmacists, Inc.